MESSINA, ROBERTA
 Distribuzione geografica
Continente #
EU - Europa 1.835
NA - Nord America 1.782
AS - Asia 1.738
SA - Sud America 382
Continente sconosciuto - Info sul continente non disponibili 175
AF - Africa 30
OC - Oceania 4
Totale 5.946
Nazione #
US - Stati Uniti d'America 1.689
RU - Federazione Russa 1.113
SG - Singapore 595
CN - Cina 565
BR - Brasile 309
IT - Italia 286
HK - Hong Kong 194
VN - Vietnam 161
SE - Svezia 138
BD - Bangladesh 86
FR - Francia 70
DE - Germania 57
CA - Canada 43
GB - Regno Unito 36
AR - Argentina 32
MX - Messico 30
IN - India 28
FI - Finlandia 21
IE - Irlanda 18
PL - Polonia 18
ES - Italia 15
EC - Ecuador 13
ID - Indonesia 13
JP - Giappone 12
TR - Turchia 12
NL - Olanda 11
CO - Colombia 9
ZA - Sudafrica 9
AT - Austria 8
IQ - Iraq 8
JO - Giordania 8
UA - Ucraina 8
LT - Lituania 7
MY - Malesia 7
RS - Serbia 7
CL - Cile 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
TW - Taiwan 5
AU - Australia 4
CR - Costa Rica 4
DK - Danimarca 4
GR - Grecia 4
KR - Corea 4
PE - Perù 4
PK - Pakistan 4
UZ - Uzbekistan 4
CH - Svizzera 3
HN - Honduras 3
JM - Giamaica 3
KE - Kenya 3
KZ - Kazakistan 3
MA - Marocco 3
NO - Norvegia 3
PY - Paraguay 3
TN - Tunisia 3
VE - Venezuela 3
ZW - Zimbabwe 3
BE - Belgio 2
CZ - Repubblica Ceca 2
DO - Repubblica Dominicana 2
KW - Kuwait 2
LC - Santa Lucia 2
NG - Nigeria 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
SV - El Salvador 2
TH - Thailandia 2
UY - Uruguay 2
AI - Anguilla 1
AO - Angola 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
BW - Botswana 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
DZ - Algeria 1
EG - Egitto 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
GH - Ghana 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
MK - Macedonia 1
MW - Malawi 1
NI - Nicaragua 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 5.773
Città #
Dallas 398
Singapore 306
Moscow 212
Ashburn 198
Hong Kong 190
San Jose 132
Council Bluffs 110
Shanghai 94
Milan 73
Hefei 72
New York 72
Ho Chi Minh City 57
Lauterbourg 56
Beijing 51
Los Angeles 48
São Paulo 41
Santa Clara 39
Lawrence 38
Princeton 38
Rome 38
Munich 25
Hanoi 23
Boardman 21
Orem 21
Denver 19
Dublin 18
Warsaw 17
Montreal 15
Guangzhou 14
Turin 13
Chennai 12
Nuremberg 12
Atlanta 11
Florence 11
Seattle 11
Stockholm 11
Biên Hòa 10
Buffalo 10
Chicago 10
Curitiba 10
Houston 10
Helsinki 9
Manchester 9
Mexico City 9
Phoenix 9
Tokyo 9
Amman 8
Genoa 8
Poplar 8
Tianjin 8
Ankara 7
Belgrade 7
Haiphong 7
Hải Dương 7
Turku 7
Washington 7
Brasília 6
Brooklyn 6
Cincinnati 6
Da Nang 6
Johannesburg 6
Naples 6
Omaha 6
Perugia 6
Querétaro 6
Belo Horizonte 5
Bergamo 5
Betim 5
Bogotá 5
Hangzhou 5
Lappeenranta 5
London 5
Padua 5
Philadelphia 5
Porto Alegre 5
Quito 5
Recife 5
Rho 5
Ribeirão das Neves 5
Rio de Janeiro 5
Shenzhen 5
St Louis 5
Amsterdam 4
Baghdad 4
Bologna 4
Boston 4
Calgary 4
Charlotte 4
Falkenstein 4
Guayaquil 4
Kuala Lumpur 4
Marostica 4
Mumbai 4
Néa Smýrni 4
Olímpia 4
Passo Fundo 4
Pisa 4
San Francisco 4
St Petersburg 4
Tashkent 4
Totale 2.897
Nome #
A novel scoring approach to identify responders to erenumab in clinical practice 185
Resting State Functional Connectivity Changes of the Pons in Migraine Patients: A Cross-Sectional and Longitudinal Study 176
Extent and characteristics of carotid plaques and brain parenchymal loss in asymptomatic patients with no indication for revascularization 174
Alterations of brain structural MRI are associated with outcome of surgical treatment in trigeminal neuralgia 173
Efficacy and safety of anti-CGRP monoclonal antibodies for chronic migraine prophylaxis in patients treated with botulinum toxin A: A prospective monocentric study 167
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II) 154
Assessing the role of innovative therapeutic paradigm on multiple sclerosis treatment response 123
The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN) 122
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients 120
Imaging the brain and vascular reactions to headache treatments: a systematic review 120
Comparison of efficacy and safety of erenumab between over and under 65-year-old refractory migraine patients: a pivotal study 114
Imaging of Migraine and Vestibular Migraine 113
Brain connectivity abnormalities extend beyond the sensorimotor network in peripheral neuropathy 103
Biomarkers of Migraine and Cluster Headache: Differences and Similarities 101
Tension-type headache 98
An update on migraine: current understanding and future directions 98
Clinical correlates of hypothalamic functional changes in migraine patients 95
Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience 93
CGRP – a target for acute therapy in migraine: Clinical data 91
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study 90
Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report 89
Cervical Cord T1-weighted Hypointense Lesions at MR Imaging in Multiple Sclerosis: Relationship to Cord Atrophy and Disability 86
Stress in paediatric migraine: a trigger factor? 86
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life study 85
Candesartan in migraine prevention: results from a retrospective real-world study 85
Functional MRI in migraine 84
Phase III, randomised, double-blind, placebo-controlled trial of Neuroaspis plp10 as an adjuvant treatment for relapsing multiple sclerosis: the MINERAL Study 82
Tracking the evolution of non-headache symptoms through the migraine attack 81
Cortical abnormalities in patients with migraine: a surface-based analysis. 79
Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study 78
DIFFERENCES IN BRAIN STRUCTURE AND FUNCTION IN PRIMARY HEADACHE DISORDERS: A MULTIMODAL MRI STUDY 76
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study 75
Brain structural and functional abnormalities in Fahr's disease: a report of two cases 74
Dysregulation of multisensory processing stands out from an early stage of migraine: a study in pediatric patients 74
Erenumab effect on brain network function in episodic migraine patients: a randomized, placebo-controlled, clinical trial 73
Neural correlates of visuospatial processing in migraine: does the pain network help? 72
Evaluating the Effectiveness, Tolerability, and Safety of Eptinezumab in High-Frequency and Chronic Migraine in Real World: EMBRACE—The First Italian Multicenter, Prospective, Real-Life Study 71
A review of recent literature on functional MRI and personal experience in two cases of definite vestibular migraine 67
A novel scoring approach to identify responders to erenumab in clinical practice 66
Insights into migraine attacks from neuroimaging 65
An Altered Hypothalamic-Pontine Functional Interplay Could Affect Migraine Disease Progression Over the Years 65
Influence of the topography of brain damage on depression and fatigue in patients with multiple sclerosis. 63
What imaging has revealed about migraine and chronic migraine 62
Relation between characteristics of carotid atherosclerotic plaques and brain white matter hyperintensities in asymptomatic patients 62
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE) 58
Unveiling Functional and Structural Brain MRI Alterations in Opioid Use Disorder 58
Structural brain abnormalities in patients with vestibular migraine 58
The Chronic Migraine Brain: What Have We Learned From Neuroimaging? 58
Regional cervical cord atrophy and disability in multiple sclerosis: a voxel-based analysis. 57
Pathophysiological Bases of Comorbidity in Migraine 57
Editorial: Functional and Structural Brain Alterations in Headache: A Trait or a State? 56
Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations 55
Author response: Gray matter volume modifications in migraine: A cross-sectional and longitudinal study 55
Refractory chronic migraine: is drug withdrawal necessary before starting a therapy with onabotulinum toxin type A? 54
What We Gain From Machine Learning Studies in Headache Patients 54
Recent advances in headache neuroimaging 53
Gray matter volume modifications in migraine: A cross-sectional and longitudinal study 53
White matter microstructure abnormalities in pediatric migraine patients 48
Editorial: Still Searching for the Origin of Migraine: From Comorbidities to Chronicization 45
Multiple sclerosis imaging: recent advances. 45
Resting-state fMRI functional connectivity: a new perspective to evaluate pain modulation in migraine? 44
Imaging the migrainous brain: the present and the future 44
Biomarkers of treatment response 41
Structural brain MRI abnormalities in pediatric patients with migraine 41
Imaging of migraine and vestibular migraine 41
Exploring the role of the pons and hypothalamus in migraine disease progression 40
Estimating brain lesion volume change in multiple sclerosis by subtraction of magnetic resonance images 40
fMRI of the sensorimotor system 40
fMRI of pain 39
MRI studies can predict progression of disease years before it occurs 38
Resting State Functional Connectivity Changes of the Hypothalamus in Migraine Patients: A Cross-Sectional and Longitudinal Study 36
Neural Correlates of Visuospatial Processing in Migraine Patients: Does the Pain Network Interfere? 35
Resting State Functional Connectivity Changes of the Hypothalamus in Migraine Patients: A Cross-Sectional and Longitudinal Study 34
Neural correlates of visuospatial processing in migraine patients: does the pain network interfere? 33
Neural correlates of visuospatial processing in migraine patients: does the pain network interfere? 31
RESTING STATE FUNCTIONAL CONNECTIVITY CHANGES OF THE HYPOTHALAMUS IN MIGRAINE PATIENTS: A CROSS-SECTIONAL AND LONGITUDINAL STUDY 29
Super- and absolute responders to anti-cgrp monoclonal antibodies in migraine: A one-year multicenter, prospective, observational study 27
Migraine treatments: what have we learned from neuroimaging? 25
Insights into Migraine Treatments. Towards Personalized Medicine 22
Interventions for Migraine and Sleep: A Systematic Review Exploring Their Bidirectional Association 16
Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis 14
Unveiling Resting-State Functional Connectivity Patterns in Patients With Migraine: A REFORM Study 13
Influence of next-generation artificial intelligence on headache research, diagnosis and treatment: the junior editorial board members’ vision – part 1 13
Worldwide availability of medications for migraine and tension-type headache: A survey of the International Headache Society 8
Combining treatments for migraine prophylaxis: the state-of-the-art 6
Real-World Response and Super-Response to Eptinezumab over 48 Weeks in Migraine: The Prospective Multicenter EMBRACE III Study 6
Health equity, care access and quality in headache – part 2 5
Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials 4
Exploring the role of the pons and hypothalamus in migraine progression 4
Exploring the role of the pons and hypothalamus in migraine progression 3
Totale 5.946
Categoria #
all - tutte 31.242
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.242


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 1 1 11 0 4 5 2 1 1 6 2
2022/2023255 88 50 26 1 7 29 15 18 7 1 7 6
2023/2024258 6 11 31 22 41 36 8 32 7 9 16 39
2024/2025925 95 23 28 23 44 85 77 91 141 154 71 93
2025/20264.007 258 312 419 511 270 147 283 274 1.035 186 166 146
2026/2027432 220 212 0 0 0 0 0 0 0 0 0 0
Totale 5.946